144 related articles for article (PubMed ID: 23705836)
1. Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing.
Pellegatti M
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1171-80. PubMed ID: 23705836
[TBL] [Abstract][Full Text] [Related]
2. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
[TBL] [Abstract][Full Text] [Related]
3. Investigative safety science as a competitive advantage for Pharma.
Moggs J; Moulin P; Pognan F; Brees D; Leonard M; Busch S; Cordier A; Heard DJ; Kammüller M; Merz M; Bouchard P; Chibout SD
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1071-82. PubMed ID: 22769724
[TBL] [Abstract][Full Text] [Related]
4. Advances in the development and use of human tissue-based techniques for drug toxicity testing.
Clotworthy M; Archibald K
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1155-69. PubMed ID: 23687950
[TBL] [Abstract][Full Text] [Related]
5. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
Box RJ; Spielmann H
Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
[TBL] [Abstract][Full Text] [Related]
6. Reducing attrition in drug development: smart loading preclinical safety assessment.
Roberts RA; Kavanagh SL; Mellor HR; Pollard CE; Robinson S; Platz SJ
Drug Discov Today; 2014 Mar; 19(3):341-7. PubMed ID: 24269835
[TBL] [Abstract][Full Text] [Related]
7. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
8. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
[TBL] [Abstract][Full Text] [Related]
9. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
Kroeger M
Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220
[TBL] [Abstract][Full Text] [Related]
10. Computational toxicology--a tool for early safety evaluation.
Merlot C
Drug Discov Today; 2010 Jan; 15(1-2):16-22. PubMed ID: 19835978
[TBL] [Abstract][Full Text] [Related]
11. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.
Donato MT; Gómez-Lechón MJ; Tolosa L
Expert Opin Drug Discov; 2017 Feb; 12(2):201-211. PubMed ID: 27936962
[TBL] [Abstract][Full Text] [Related]
12. Concise review: Human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment.
Sartipy P; Björquist P
Stem Cells; 2011 May; 29(5):744-8. PubMed ID: 21433222
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
14. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
Stevens JL
Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
[TBL] [Abstract][Full Text] [Related]
15. Stem cell models for drug discovery and toxicology studies.
Liu W; Deng Y; Liu Y; Gong W; Deng W
J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
[TBL] [Abstract][Full Text] [Related]
16. Drug-mediated toxicity: illuminating the 'bad' in the test tube by means of cellular assays?
Tralau T; Luch A
Trends Pharmacol Sci; 2012 Jul; 33(7):353-64. PubMed ID: 22554615
[TBL] [Abstract][Full Text] [Related]
17. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
18. Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations.
Bailey J; Balls M
BMC Med Ethics; 2019 Mar; 20(1):16. PubMed ID: 30823899
[TBL] [Abstract][Full Text] [Related]
19. What have we learned from pre-clinical juvenile toxicity studies?
Bailey GP; Mariën D
Reprod Toxicol; 2009 Sep; 28(2):226-9. PubMed ID: 19446432
[TBL] [Abstract][Full Text] [Related]
20. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.
Morford LL; Bowman CJ; Blanset DL; Bøgh IB; Chellman GJ; Halpern WG; Weinbauer GF; Coogan TP
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):359-80. PubMed ID: 21770023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
